evipedia.ai
← Back

Gotu Kola for Health & Longevity

Evidence Review created on 09/10/2026 using AI4L / Opus 5

Also known as: Centella asiatica, Asiatic Pennywort, Indian Pennywort, Mandukaparni, Brahma Manduki, Tiger Grass, TECA, TTFCA, ECa 233

Motivation

Gotu Kola is a small creeping marsh plant that grows across the wet tropics of Asia, Africa and Australia. Its leaves are eaten as a green vegetable in Sri Lanka and Thailand and have been brewed as a tonic for centuries. Modern interest centers on a group of plant compounds it makes in unusually large amounts, which appear to act on collagen and on the lining of the smallest blood vessels.

The plant carries an old reputation as a herb of long life, and current attention follows two threads: the condition of leg veins and skin, and the aging brain. Standardized extracts have been sold as regulated medicines in parts of Europe and Asia for decades, while elsewhere the same plant is sold as a dietary supplement of widely varying strength and composition.

This review examines what the evidence shows about Gotu Kola: which of its claimed effects rest on controlled human studies, which rest on laboratory and animal work, what is known about its safety, and how far the extracts that were studied differ from the products on sale.

Benefits - Risks - Protocol - Conclusion

High-level overviews of Gotu Kola from expert publications and narrative scientific reviews that discuss the plant and its constituents in depth.

Of the six priority sources, only Life Extension carries content that discusses Gotu Kola by name in substantial depth. Rhonda Patrick, Peter Attia, Andrew Huberman and Lifespan.io have published nothing on the herb, and Chris Kresser mentions it only in passing within articles on other subjects, so no item from those five platforms could be listed.

Grokipedia

  • Centella asiatica

    The site’s primary article on the plant, covering botany, distribution, traditional use and pharmacology, and useful as a single orientation point before reading the clinical literature.

Examine

  • Gotu Kola

    Grades outcomes against 15 trials in 797 participants, giving its highest grade to chronic venous insufficiency signs (failing leg vein valves) while noting the absence of human cognitive-enhancement data behind the popular claim.

ConsumerLab

ConsumerLab has not published a dedicated Gotu Kola review, Answer, or ingredient page, so no article exists to link. The herb has never been the subject of one of its comparative product tests, meaning no independent purity or label-accuracy data on Gotu Kola supplements is available from this source.

Systematic Reviews

Systematic reviews and meta-analyses covering the principal claimed benefits of Gotu Kola and its principal documented harm.

Both sides of the trade-off are represented: reviews exist for the claimed effects and for the principal risk, hepatotoxicity.

Mechanism of Action

Gotu Kola’s activity is attributed chiefly to four pentacyclic triterpenes — asiaticoside and madecassoside, and their aglycones asiatic acid and madecassic acid — plus a second class, the caffeoylquinic acids.

The best-supported action is on connective tissue. The triterpenes drive fibroblasts to synthesize type I collagen while restraining the enzymes that degrade it, thickening the fibrous cap over vascular plaque, tightening the venous wall and speeding wound closure. A parallel action on the capillary wall cuts fluid leakage into tissue, the proposed basis for reduced ankle swelling.

In the nervous system the mechanism differs. The caffeoylquinic acids activate Nrf2 (a master switch turning on the cell’s own antioxidant genes), while the triterpenes increase mitochondrial biogenesis and promote dendritic branching, apparently through the MAPK and Akt cascades (chains of proteins relaying growth signals inside a cell) and BDNF (brain-derived neurotrophic factor, which supports neuron survival and branching).

Readings of the anti-inflammatory data compete: most work reports suppression of NF-κB (a control switch for inflammatory genes), while cell studies cited by Examine describe enhanced release of the inflammatory signal interleukin-1β.

Pharmacologically, asiaticoside and madecassoside are barely absorbed; gut bacteria hydrolyze them to asiatic and madecassic acid, which peak in plasma near two hours and clear with a short half-life that lengthens on repeated dosing, asiatic acid accumulating over seven days. Distribution includes the brain in animal models, the triterpenes are selective for no single receptor, and elimination is largely hepatic and fecal.

Historical Context & Evolution

Gotu Kola entered written medicine through Ayurveda as mandukaparni, a medhya rasayana — a rejuvenating agent for the intellect — and appears in the Chinese materia medica and in Sri Lankan and Thai food traditions, where the leaf is eaten raw as a salad green. Its original use was therefore twofold: nerve tonic and everyday vegetable. Topical application to wounds, ulcers and leprosy lesions is documented across the same regions.

The modern pharmaceutical story begins in France in the late 1940s, when Boiteau and Ratsimamanga isolated asiaticoside and developed it into a wound preparation. From the 1960s a titrated triterpene fraction was registered as a prescription or pharmacy medicine in France, Italy, Spain and Korea under names such as Madecassol and Centellase, indicated for venous insufficiency and scars — a status never obtained in the United States.

The clinical literature then split. European vascular research of the 1980s and 1990s, much of it from one Italian group, built the venous and plaque case. A separate strand, from the Thai cognitive trials of the 2000s to the Oregon program, pursued the traditional brain claim and has failed to replicate a cognitive benefit while identifying plausible molecular targets.

The wound and venous findings have not been overturned; what changed is the standard of proof applied to them. The current position — vascular evidence suggestive but limited by reporting quality, cognitive evidence negative — reflects better trial appraisal rather than contradicting trials, and caffeoylquinic acid research may yet reopen the cognitive question.

Expected Benefits

High 🟩 🟩 🟩

Chronic Venous Insufficiency Signs and Symptoms

Standardized triterpene extracts reduce leg heaviness, ankle swelling, pain and cramping in chronic venous insufficiency (CVI, in which leg vein valves fail and blood pools). The proposed mechanism is reduced capillary leakage plus increased venous wall tone. The evidence base is eight randomized controlled trials pooled in a systematic review, supported by the Cochrane review of venoactive agents (agents that tone the vein wall and curb capillary leakage). Most trials were small and incompletely reported, and Cochrane rated the certainty of venoactive-agent evidence as low to moderate.

Magnitude: In an eight-week double-blind trial in 94 patients, 120 mg/day improved leg heaviness and swelling versus placebo (p<0.05 — a p-value being the probability that a result this large would arise by chance alone), while venous distensibility improved on the extract and worsened on placebo; a dose-ranging trial found 180 mg/day reduced capillary filtration rate more than 90 mg/day.

Facial Wrinkle Depth and Skin Hydration

Both topical and oral preparations measurably reduce wrinkle depth and raise skin water content, consistent with the collagen-synthesis mechanism. A network meta-analysis of five double-blind randomized trials in 172 women found the herb more effective than one botanical comparator and probably less effective than tretinoin, with hydration gains that tretinoin did not produce. A separate 12-week oral trial in 112 middle-aged women replicated the wrinkle effect. All participants to date have been Asian women, so generalization is untested.

Magnitude: Oral supplementation at 200 mg/day for 12 weeks reduced average wrinkle depth 11.1%, largest-wrinkle depth 14.4%, total wrinkle volume 13.7% and surface roughness 10.4% from baseline; skin elasticity and brightness improved versus placebo (p<0.05) but by under 1%.

Medium 🟩 🟩

Wound and Post-Procedure Skin Healing

Applied topically or taken orally around a skin injury, the extract speeds re-epithelialization and reduces redness and crusting. The mechanism is stimulation of collagen I, fibroblast growth factor and vascular endothelial growth factor with suppression of inflammatory signals. A systematic review found only four clinical trials, too heterogeneous to pool. The strongest single study is a blinded split-face trial after laser resurfacing; an oral trial in diabetic wounds found better contraction but poorer granulation, so the picture is not uniform.

Magnitude: In the split-face trial, the treated side showed a lower erythema index (a measure of skin redness) across follow-up (coefficient -0.03, 95% CI -0.06 to -0.0006; p=0.046 — a confidence interval being the range within which the true effect probably lies), with physician-rated wound appearance better at days 2, 4 and 7.

Diabetic Neuropathy Symptom Relief

A standardized triterpene extract reduced the symptoms of symmetrical diabetic neuropathy (nerve damage from long-standing high blood glucose causing tingling, numbness, pain and burning). The proposed mechanism combines improved microcirculation with the neurotropic effects seen in laboratory models. The evidence is a single 52-week randomized, double-blind, placebo-controlled trial in 43 people with type 2 diabetes, described by its authors as a pilot. Plasma triterpene concentrations matched the neurotropic range observed in cell studies, which supports the causal reading but does not replace replication.

Magnitude: Total symptom score and paresthesia (pins-and-needles tingling) fell significantly from baseline only in the treated group, and numbness rose from baseline in the placebo group and was significantly worse there than in the treated group; the trial reports significance levels only and gives no outcome figure for the size of the symptom change.

Lower-Extremity Strength in Older Adults

Two months of a standardized whole-plant extract improved lower-limb strength and one physical-function quality-of-life subscale in healthy older adults, a functional endpoint directly relevant to preserving independence. The proposed basis is the plant’s antioxidant activity offsetting oxidative contributions to physical decline. The evidence is a single randomized, double-blind, placebo-controlled trial in 80 healthy elderly participants across three doses. It has not been replicated by an independent group, and the effect faded one month after the extract was stopped.

Magnitude: After two months, 500 mg/day and 750 mg/day increased 30-second chair-stand performance, the 6-minute walk and hand-grip measures did not change, and only the higher doses moved the life-satisfaction subscale; the trial reports F-statistics (a ratio comparing differences between groups to variation within them) and significance levels only and gives no outcome figure for the strength gain.

Low 🟩

Acute Alertness and Anger Reduction ⚠️ Conflicted

A single dose lifts self-rated alertness and lowers anger within an hour without improving cognition. The meta-analysis of eleven trials found the mood signal but no memory benefit; an older trial reported working-memory gains at 750 mg/day. Net reading: the mood effect is real but small, the cognitive claim unsupported.

Magnitude: Alertness standardized mean difference 0.71 (95% CI 0.01 to 1.41) and anger -0.81 (95% CI -1.51 to -0.09) at one hour — a standardized mean difference expressing effect size in units of the outcome’s own spread.

Anxiety and Stress Symptom Reduction

Standardized extract reduced anxiety, stress and depression scores in generalized anxiety disorder over 60 days, matching traditional calming use and the blunted startle response. The evidence is one uncontrolled open-label study in 33 adults with no placebo arm, so improvement over time cannot be separated from placebo response.

Magnitude: Anxiety, stress and depression scores fell significantly from baseline at days 30 and 60 (p<0.01 for each); with no control group the trial reports no between-group effect size.

Carotid and Femoral Plaque Stabilization ⚠️ Conflicted

Added to pine bark extract, Gotu Kola slowed arterial plaque progression and raised plaque density on ultrasound, an unvalidated surrogate. Every dataset comes from one Italian group funded by the ingredients’ maker, Horphag Research, and the key studies were open-label. Net reading: consistent in direction but unreplicated and commercially conflicted.

Magnitude: Over 30 months, 1.1% of plaques progressed from class IV to V on the combination versus 21.3% on lifestyle measures alone and 16.6% on aspirin; a 42-month extension reported 6.5% versus 48% progression to symptomatic disease.

Speculative 🟨

Neuroprotective Signaling in the Aging Brain

Aqueous extract activates Nrf2 genes, raises mitochondrial respiration and restores dendritic branching in aged mice, with target engagement shown in humans. No controlled study shows a human outcome; the basis is mechanistic and animal only.

Benefit-Modifying Factors

  • Gut microbial conversion capacity: Asiaticoside and madecassoside are inert until intestinal bacteria strip their sugar groups. People whose microbiome converts poorly, including those recently treated with broad-spectrum antibiotics, will generate less asiatic and madecassic acid from an identical dose.

  • Genetic polymorphisms: No variant has been shown to modify the benefit. Differences in CYP3A4 and CYP2C9 activity (liver enzymes that clear many drugs) are a plausible determinant of how much active triterpene circulates, but have never been tested against response.

  • Baseline venous pressure and capillary filtration: The venous benefit tracks how abnormal the starting state is. Trials found no change in capillary filtration in participants with normal veins given the same dose that improved it in those with venous hypertension.

  • Baseline skin condition and sun damage: Wrinkle and hydration gains were measured in women with established photoaging. Someone with minimal existing wrinkle depth has proportionally less to recover, and the reported absolute changes were under 1% for elasticity.

  • Sex: No human trial has reported sex-stratified results, and the wrinkle and venous trials enrolled almost entirely women. Mouse work found cognitive and anxiety effects varied by sex, dose and route, so equivalence in men is assumed, not shown.

  • Pre-existing conditions: Benefit is largest where a target pathology exists — venous insufficiency, diabetic neuropathy, healing wounds. In metabolically healthy people the only adequately powered metabolic trial, in type 2 diabetes, found no change in blood glucose or cholesterol.

  • Age: Older adults were the population in which strength and quality-of-life gains appeared, and pharmacokinetic work in the elderly found no dose adjustment necessary. Those over 75 remain under-represented in every trial.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Upset

Mild nausea, abdominal discomfort and loose stools are the most frequently recorded adverse events with oral use, and the only ones reported at meaningful frequency in controlled trials. The likely mechanism is direct mucosal irritation by saponin-type triterpenes. Documented in a six-month randomized placebo-controlled trial in type 2 diabetes and in the phase 1 tolerability work in cognitively impaired older adults. Symptoms were transient in every case and no participant discontinued for them, so severity is low even where frequency is not.

Magnitude: 5 of 34 participants (14.7%) reported mild transient gastrointestinal symptoms over six months at 1,200 mg/day, with no serious adverse events; single doses of 2 g and 4 g of aqueous extract were tolerated without gastrointestinal dropout.

Medium 🟥 🟥

Allergic Contact Dermatitis

Topical preparations can sensitize the skin, producing an itching, scaling eczematous reaction on repeated exposure. Asiaticoside is the usual sensitizer, and cross-reaction with fragrance allergens in the same cosmetic base is common. Documented in patch-tested case reports and reviewed by the Cosmetic Ingredient Review Expert Panel — funded by the cosmetics trade association whose members sell these ingredients — which judged them safe only when formulated to be non-sensitizing. Reactions resolve on withdrawal but recur on re-exposure, and sensitization is permanent.

Magnitude: Risk arises almost exclusively with repeated topical or cosmetic exposure rather than oral use, and rises with concentration and with damaged skin; the published literature consists of individual cases and small patch-test series rather than prevalence surveys, and reports no incidence figure.

Drug-Induced Liver Injury

Oral use has been linked to hepatitis with jaundice and raised liver enzymes, occasionally severe. A systematic review of Latin American reports names Centella asiatica among the most frequently implicated herbal products, most often in women taking it for months. Several published cases recurred on inadvertent re-exposure, which is the strongest causality signal available for this class of injury.

Magnitude: Injury is confined to prolonged oral use, with onset from weeks to months and recurrence on inadvertent re-exposure; the literature consists of case reports and case series and reports no incidence rate.

Low 🟥

Drowsiness and Impaired Alertness

Traditional sedative use and animal data predict central depression at higher doses. A controlled human study found a single 12 g dose blunted the startle response without altering self-rated mood, heart rate or blood pressure.

Magnitude: Sedation appears dose-dependent and additive with alcohol and other sedating agents; the human evidence measures a startle reflex rather than driving or vigilance, and reports no figure for clinically relevant impairment.

Speculative 🟨

Reproductive and Developmental Effects

Traditional sources call the plant an emmenagogue (an agent that brings on menstruation), and no human pregnancy data exist. Rodent work found no organ toxicity; the basis here is tradition and animal work only.

Risk-Modifying Factors

  • Pre-existing liver disease: Any active hepatitis, fatty liver with raised transaminases (enzymes that leak from injured liver cells), or cirrhosis narrows the reserve available to absorb an idiosyncratic injury, and makes attribution harder if enzymes rise during use.

  • Baseline liver enzymes: A person starting with alanine aminotransferase already above the functional range loses the clearest early warning signal, since a further rise cannot be distinguished from ongoing background elevation.

  • Sex: Published liver-injury cases are predominantly in women, though this partly reflects who takes the herb. No sex difference in gastrointestinal or dermatological adverse events has been demonstrated.

  • Concurrent hepatotoxic exposure: Regular alcohol, acetaminophen, methotrexate, or stacking with other liver-implicated botanicals such as green tea extract raises the combined burden on a shared elimination route.

  • Atopic or fragrance-sensitized skin: Existing eczema or established fragrance allergy raises the chance of sensitization to topical preparations, because the barrier is impaired and cosmetic bases carry cross-reacting allergens.

  • Age: Older adults tolerated 250 to 750 mg/day for three months without excess adverse events, but reduced hepatic reserve and heavier concurrent medication use make interaction-driven problems more likely past 70.

  • Genetic polymorphisms: No variant has been validated as modifying Gotu Kola risk. Slower CYP2C9 or CYP3A4 metabolizers are a theoretical concern only, since the triterpenes inhibit these enzymes in cell studies.

Key Interactions & Contraindications

  • Sedatives and central nervous system depressants: Benzodiazepines (diazepam, lorazepam), barbiturates (phenobarbital, butalbital), zolpidem and alcohol. Caution; additive drowsiness and impaired coordination. Mitigation is separation from driving and discontinuation two weeks before general anesthesia.

  • Hepatotoxic medications: Acetaminophen, methotrexate, isoniazid, amiodarone, high-dose statins (atorvastatin, simvastatin). Caution; additive risk of liver injury. Mitigation is a liver panel before starting and at eight weeks, with discontinuation if enzymes rise.

  • Glucose-lowering medications: Metformin, sulfonylureas (glipizide, glyburide), insulin. Monitor; a theoretical additive fall in blood glucose. The one adequately powered trial found no glycemic effect, so the concern is precautionary rather than demonstrated.

  • Diuretics: Furosemide, hydrochlorothiazide. Monitor; the herb has mild diuretic activity that could add to fluid and electrolyte loss. No timing adjustment is needed, though standing blood pressure is the relevant measure to follow.

  • Substrates of CYP3A4 and CYP2C9: Statins (simvastatin, atorvastatin), warfarin, some calcium channel blockers (amlodipine, felodipine). Caution; extracts inhibit these drug-clearing enzymes in cell studies, which could raise substrate concentrations. No human interaction study exists; mitigation is separating doses by at least two hours.

  • Over-the-counter sedating antihistamines: Diphenhydramine, doxylamine, chlorpheniramine, and combination sleep or cold preparations containing them. Caution; additive sedation and next-morning grogginess, particularly at Gotu Kola doses above 1 g.

  • Over-the-counter acetaminophen: Present in most combination cold, flu and pain preparations, which makes unintentional stacking easy. Caution; shared potential for hepatocellular injury (damage to the liver cells themselves). A total acetaminophen ceiling of 2 g daily is the usual mitigation during supplementation.

  • Sedating and calming supplements: Kava, valerian, passionflower, melatonin, ashwagandha and high-dose magnesium. Caution; additive drowsiness. Introducing Gotu Kola alone for two weeks before adding any of these allows effects to be attributed correctly.

  • Venoactive supplements with additive effects: Horse chestnut seed extract, diosmin-hesperidin, butcher’s broom and pine bark extract all reduce capillary leakage by overlapping routes. Monitor; additive benefit is plausible, but an excessive reduction in leg swelling can mask heart or kidney problems.

  • Liver-implicated botanicals: Green tea extract, kava, black cohosh, garcinia and comfrey. Caution; additive hepatocellular risk from stacking products that independently appear in liver-injury case series. Avoidance of concurrent use is safer than monitoring through it.

  • Bacopa monnieri: Marketed interchangeably with Gotu Kola and frequently combined in nootropic blends. Monitor; overlapping sedative and cholinergic effects. No trial has tested the combination, so any additive benefit is unverified.

  • Topical retinoids: Tretinoin, adapalene and retinol used on the same skin area. Caution; both act on collagen turnover and both irritate. Applying them on alternate evenings rather than together limits cumulative irritation.

Populations who should avoid Gotu Kola:

  • Pregnancy and breastfeeding, at any dose and by any route, given the traditional emmenagogue reputation and the complete absence of human safety data
  • Active hepatocellular disease, or any liver impairment at Child-Pugh Class B or C
  • Anyone with alanine aminotransferase or aspartate aminotransferase above twice the upper reference limit at baseline
  • Prior hepatitis attributed to Gotu Kola or to any Apiaceae-family botanical, given documented recurrence on re-exposure
  • Known allergy to Gotu Kola, asiaticoside, or other Apiaceae plants such as celery, carrot or parsley
  • Scheduled surgery within 14 days, because of additive sedation with anesthetic agents
  • Children under 18, in whom no dose has been established in any trial

Risk Mitigation Strategies

  • Baseline and follow-up liver panel: Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and bilirubin, measured before the first dose and again at 8 weeks, then every 6 months, catch drug-induced liver injury while it is still asymptomatic.

  • Single-ingredient product first: A standardized single-herb capsule rather than a nootropic or venous blend allows any gastrointestinal upset, sedation or enzyme rise to be attributed to Gotu Kola rather than to a co-ingredient.

  • Low starting dose with slow titration: Protocols typically begin at 250 mg once daily with food for two weeks before increasing to the target range, which limits the mild transient gastrointestinal symptoms reported in roughly 15% of trial participants.

  • Evening dosing on introduction: Placing the first two weeks’ doses in the evening keeps any drowsiness or blunted alertness outside working and driving hours, with reassessment before any shift to daytime dosing.

  • Patch test before topical use: Applying the preparation to a coin-sized area of inner forearm for three consecutive days before facial or wound use reveals allergic contact dermatitis before a larger or more visible area is sensitized.

  • Cap concurrent hepatic load: Total acetaminophen under 2 g daily, limited alcohol, and no stacking of green tea extract, kava or other liver-implicated botanicals keep any single elimination route from carrying several simultaneous insults.

  • Two-week washout before surgery: Stopping all Gotu Kola 14 days before any procedure requiring general anesthesia or sedation, with the anesthetist informed, prevents additive central nervous system depression.

  • Stop rule for symptoms: Immediate discontinuation and a liver panel on any dark urine, right upper abdominal pain, unexplained fatigue lasting more than a few days, or yellowing of skin or eyes, rather than waiting for the scheduled test.

Therapeutic Protocol

  • Standardized triterpene fraction for venous use: The European pharmaceutical protocol, established with Madecassol and Centellase, gives 60 mg of titrated triterpene extract two or three times daily, for a total of 120 to 180 mg/day over 4 to 12 weeks.

  • Whole-plant extract for general use: The Khon Kaen University protocols used 250, 500 or 750 mg of standardized whole-plant extract once daily for 60 to 90 days, with strength and mood effects appearing only at 500 mg and above.

  • ECa 233 standardized extract: The Chulalongkorn University preparation, standardized to 80% triterpenes with madecassoside and asiaticoside in fixed ratio, has been given at 250 to 500 mg/day in phase 1 and clinical work.

  • Aqueous extract for neurological research: The Oregon Health & Science University program administers 2 g to 4 g of a standardized aqueous extract product as a single dose, a research protocol rather than an established therapeutic one.

  • Competing approaches: Conventional venous care uses compression stockings and micronized flavonoids; the botanical approach substitutes or adds triterpene extract. Neither has been shown superior, and the trials underpinning each were run by different research communities.

  • Half-life and dose splitting: Asiatic acid peaks near two hours and clears quickly after one dose, but half-life and peak concentration rise after seven days of twice-daily use. Divided dosing suits this profile better than a single daily dose.

  • Best time of day: Dosing with meals suits the lipophilic triterpenes and the gut bacteria that must act on the glycosides; where drowsiness occurs, the larger share of a split dose falls in the evening.

  • Genetic polymorphisms: No pharmacogenetic variant has been validated for Gotu Kola. APOE4, MTHFR and COMT status (genes affecting, respectively, lipid handling in the brain, folate processing and dopamine breakdown) have never been tested against response, so no dosing basis exists.

  • Sex-based differences: No human trial reports outcomes separately by sex. Mouse work found that cognitive and anxiety effects varied with sex, dose and route of administration, which is a reason for caution rather than a basis for different dosing.

  • Age-related considerations: Adults over 65 tolerated 250 to 750 mg/day for three months, and pharmacokinetic work in the elderly found no reason to reduce the dose. Above 75, polypharmacy rather than altered handling argues for a low starting dose.

  • Baseline biomarkers: Liver enzymes determine eligibility rather than dose. Where the target is venous disease, baseline ankle circumference and a symptom score provide the response measure, since no blood marker tracks the venous effect.

  • Pre-existing conditions: Venous insufficiency, diabetic neuropathy and healing wounds are the states in which controlled trials found benefit. In their absence, the expected effect is smaller and the risk-benefit balance correspondingly tighter.

Discontinuation & Cycling

  • Intended duration: Trials ran from four weeks to 52 weeks, and the European venous protocols were designed for repeated courses rather than lifelong use. No study has followed continuous use beyond one year.

  • Withdrawal effects: None documented. No trial reported rebound symptoms, and the acute mood and startle effects simply dissipate as plasma triterpenes clear, within hours to days of the last dose.

  • Tapering: Not required. Because there is no dependence and no rebound, the herb can be stopped abruptly, which is also what the stop rule for suspected liver injury demands.

  • Loss of effect on stopping: In the older-adult strength trial, the gain in lower-limb strength had faded one month after withdrawal, indicating the effect requires continued use rather than persisting as a structural change.

  • Cycling: No trial has compared continuous with cycled dosing, so any schedule is convention rather than evidence. A common pattern is 8 to 12 weeks on and 2 to 4 weeks off, which also sets a natural liver-testing point.

Sourcing and Quality

  • Standardization to total triterpenes: The only meaningful potency measure is declared content of asiaticoside, madecassoside, asiatic acid and madecassic acid. A label stating only milligrams of “herb” or a bare ratio extract cannot be matched to any trial dose.

  • Match the form to the goal: Titrated triterpene fractions were used in the venous trials, whole-plant extracts in the strength and mood trials, and an aqueous extract in the neurological work. These are not interchangeable, since the caffeoylquinic acids differ sharply between them.

  • Species substitution: Centella asiatica is confused in trade with Hydrocotyle umbellata and other pennyworts, and analytical work has been published specifically to distinguish them. A certificate of analysis naming the botanical species and the plant part is the safeguard.

  • Heavy metal accumulation: The plant grows in wetlands and takes up cadmium, lead and arsenic from water and sediment. Heavy-metal testing matters more here than for most botanicals, and matters most for products harvested wild rather than cultivated.

  • Third-party testing: The available marks are USP Verified, NSF Certified for Sport and Informed Choice, alongside an on-request certificate of analysis from an ISO 17025 laboratory. ConsumerLab has never tested this category, so no independent comparative purity data exists.

  • Reputable sources: Standardized branded extracts with published characterization include ECa 233 and Centellicum. Among retail brands, Gaia Herbs, Pure Encapsulations, Nature’s Way and Herb Pharm publish batch documentation; Life Extension also sells the herb and simultaneously publishes promotional content about it.

Practical Considerations

  • Time to effect: Alertness shifts within an hour. Venous symptoms improve over 4 to 8 weeks, wound and post-procedure effects within days, wrinkle depth over 8 to 12 weeks, and lower-limb strength after about two months of daily use.

  • Common pitfall — expecting a nootropic: The herb’s reputation as a brain tonic is not supported by the pooled trial evidence, which found no benefit in any cognitive domain. Buying it primarily to improve memory means paying for the least-supported claim.

  • Common pitfall — unstandardized product: Powdered leaf capsules and undefined ratio extracts cannot be mapped onto any trial dose, which is the single most common reason a course produces nothing.

  • Common pitfall — confusion with kola nut: Despite the name, Gotu Kola is unrelated to kola nut and contains no caffeine. Anyone expecting a stimulant will misread the mild sedation as the product failing.

  • Regulatory status: In the United States it is a dietary supplement, with no approved therapeutic indication and no premarket efficacy review. In France, Italy, Spain and Korea, titrated triterpene extracts are registered medicines, and the European Medicines Agency maintains a herbal monograph.

  • Cost and accessibility: Neither expensive nor hard to obtain. Standardized capsules cost roughly the same as a common multivitamin, and the fresh leaf is sold as a vegetable in South and Southeast Asian markets.

Interaction with Foundational Habits

  • Sleep: Direct and potentially beneficial. Traditional calming use and the blunted startle response point toward easier sleep onset, and a 2025 study found aqueous extract improved sleep quality and quantity in aged mice. No human sleep trial exists, so shifting a split dose toward evening is a pragmatic test, not a protocol.

  • Nutrition: Direct and mechanistically important. The glycosides are poorly absorbed and depend on gut bacteria for conversion, so taking capsules with a fat-containing meal and maintaining fermentable fiber intake plausibly raises the yield of active metabolites. In Sri Lanka the leaf is eaten as a salad green, a route no trial has tested.

  • Exercise: Direct and complementary. A randomized trial found improved 30-second chair-stand performance in older adults, so the herb adds to rather than blunts resistance training. For venous insufficiency it pairs naturally with calf-pump exercise and compression, which target the same failure of venous return by a mechanical route.

  • Stress management: Direct and potentiating. A placebo-controlled study showed a single dose attenuated the acoustic startle response, a physiological index of threat reactivity, and animal work reports modulation of the hypothalamic-pituitary-adrenal axis (the hormonal chain from brain to adrenal glands governing stress). This suits pairing with breathwork or meditation rather than replacing them.

Monitoring Protocol & Defining Success

Before the first dose, baseline testing has two arms — a liver panel and a measure of the outcome being pursued — because the risk needing laboratory surveillance and the benefits justifying use are measured in entirely different ways. Liver enzymes, alkaline phosphatase and bilirubin define eligibility and set the reference against which any later rise is judged. Where venous disease is the target, the baseline record is ankle circumference at a marked level and a written symptom score; where skin is the target, it is standardized photographs.

The liver panel is repeated at 8 weeks, then every 6 months, and immediately on any symptom suggesting liver injury. Outcome measures are reassessed at 8 and 12 weeks, the window in which venous, skin and strength effects appeared. Success is a measurable move in the chosen outcome with liver enzymes unchanged.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Alanine aminotransferase (ALT) 10–26 U/L (men), 7–20 U/L (women) Earliest and most specific signal of liver-cell injury Conventional laboratories flag only above 40–55 U/L, so a doubling well inside the “normal” range is easy to miss; fasting not required
Aspartate aminotransferase (AST) 10–26 U/L Confirms a liver signal and helps separate liver from muscle origin Conventional range runs to about 40 U/L, so a value well inside it can still be a meaningful rise; rises after hard exercise, so avoid strenuous training for 48 hours before the draw; interpret only alongside ALT
Alkaline phosphatase (ALP) 50–90 U/L Distinguishes bile-duct pattern injury from liver-cell pattern Conventional range extends to 130 U/L; pair with gamma-glutamyl transferase if raised, since bone also contributes
Total bilirubin 0.4–1.2 mg/dL Marks clinically significant liver injury when raised alongside enzymes Rises with fasting and with Gilbert’s syndrome (a common, harmless inherited quirk of bilirubin processing) in the absence of any liver problem; draw non-fasting if the pattern is unclear
Hemoglobin A1c (HbA1c) 4.8–5.4% Detects any drift in average blood glucose over about three months Conventional threshold for concern is 5.7%; relevant only for those taking glucose-lowering medication, since the one adequate trial found no glycemic effect
High-sensitivity C-reactive protein (hs-CRP) Below 0.5 mg/L Tracks the general inflammatory tone the herb is proposed to lower Conventional cut-off is 3.0 mg/L; a recent infection or injury invalidates the result, so repeat rather than interpret a single high value
Estimated glomerular filtration rate (eGFR) Above 90 mL/min/1.73 m² Confirms kidney function is adequate before adding any botanical Conventional laboratories flag only below 60 mL/min/1.73 m², so a substantial decline can pass unremarked; no kidney toxicity has been attributed to Gotu Kola; measure once at baseline and only repeat if other reasons arise

Qualitative markers matter as much as the laboratory panel, particularly for venous and mood outcomes where no blood test tracks the effect.

  • Leg heaviness, aching and cramping at the end of the day, recorded on a simple 0–10 scale each evening
  • Visible ankle swelling, judged by sock indentation at a consistent time of day
  • Daytime alertness and any new drowsiness, especially in the first fortnight
  • Sleep onset latency and subjective sleep quality
  • Skin texture and hydration, assessed against baseline photographs under consistent lighting
  • Wound or scar appearance where the herb is being used topically
  • Irritability and stress reactivity, which the pooled trial data suggest move before anything else does

Emerging Research

  • Target engagement trial in cognitive impairment: NCT05591027 at Oregon Health & Science University, a phase 1 study in 48 participants with mild cognitive impairment or Alzheimer’s disease, measuring the brain N-acetylaspartate to creatine ratio after six weeks — a neuronal-integrity marker rather than a cognitive outcome.

  • Endothelial function in older adults: NCT06472791 at the National University of Natural Medicine, a completed 23-participant study of endothelial function in older adults, testing whether the vascular mechanism proposed for venous disease also operates in healthy arterial aging.

  • Diabetic foot ulcer trial: NCT06531512, a phase 2/3 study in 120 participants of a Centella-containing topical preparation, with complete ulcer closure as the primary endpoint — the largest ongoing trial of the plant on a hard clinical outcome.

  • Caffeoylquinic acids as a second active class: Work from the Oregon group, reviewed by Gray et al., 2018, argues these compounds rather than the triterpenes drive the neurological effects. If correct, the triterpene-standardized products used in most trials were the wrong preparation to test the cognitive claim.

  • Sex- and route-dependent effects: Gray et al., 2024 found cognitive and anxiety effects in mice varied with sex, dose and whether the extract was given in food or water. This could explain heterogeneity across human trials, or could reveal the effects as fragile.

  • Evidence that could weaken the case: The pooled cognitive analysis of Puttarak et al., 2017 found no benefit in any domain, and the six-month trial of Tawanwongsri et al., 2025 found no effect on blood glucose or cholesterol in type 2 diabetes. Further null trials would leave only the venous and skin claims standing.

  • Bioavailability and standardization: Pharmacokinetic work by Songvut et al., 2021 showing the parent glycosides are barely absorbed has redirected effort toward reformulation and nanoencapsulation, while analytical studies address the species substitution that makes commercial products unpredictable.

Conclusion

Gotu Kola is a marsh plant, eaten as a vegetable across South and Southeast Asia, whose active plant compounds act mainly on collagen and on the walls of the smallest blood vessels. That single mechanism explains where the evidence is strongest: leg-vein symptoms and swelling, wrinkle depth and skin water content, and the healing of wounds and treated skin. Controlled human trials support these, though most were small and the skin trials enrolled only Asian women. Weaker but real signals cover diabetic nerve symptoms, leg strength in older adults, a short-lived lift in alertness, less irritability, and lower anxiety.

The traditional claim that gives the plant its reputation — that it sharpens the mind — is the one the pooled trial evidence does not support. So is any metabolic benefit. The arterial-plaque work is directionally striking but comes entirely from one research group funded by the maker of the branded ingredients, and Life Extension, the only expert publication covering the herb in depth, also sells it. The skin-safety review most often quoted is itself paid for by the industry that sells the ingredient.

Harms are mostly mild and short-lived gastrointestinal upset, with allergic skin reactions after repeated use on the skin and, rarely, liver injury during long courses of oral use — the harm that liver-enzyme monitoring is aimed at. The wider problem is that products vary so much in strength and composition that most of them cannot be matched to anything that was actually tested.

Top - Benefits - Risks - Protocol